Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors-Reference-Cited by-同舟云学术

Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors

Published:2014-10-01 Issue:4 Volume:68 Page:271-278
ISSN:0021-8820
Container-title:The Journal of Antibiotics
language:en
Short-container-title:J Antibiot

Author:

Siricilla Shajila,Mitachi Katsuhiko,Wan Bajoie,Franzblau Scott G,Kurosu Michio

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology

Link

http://www.nature.com/articles/ja2014133.pdf

Reference42 articles.

1. Nakanjako D et al. Tuberculosis and human immunodeficiency virus co-infections and their predictors at a hospital-based HIV/AIDS clinic in Uganda. Int. J. Tuberc. Lung Dis. 14, 1621–1628 (2010).

2. Diedrich CR, Flynn JL HIV-1/Mycobacterium tuberculosis co-infection immunology: How does HIV-1 exacerbate tuberculosis? Infect. Immun. 79, 1407–1417 (2011).

3. Chien JY et al. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. J. Antimicrob. Chemother. 68, 1910–1916 (2013).

4. Ranjbar S et al. HIV-1 Replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS ONE 4, e6116 (2009).

5. Connolly LE, Edelstein PH, Ramakrishnan L Why is long-term therapy required to cure tuberculosis? PLoS Med. 4, 435–442 (2003).

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Benzotriazole Derivatives: Synthesis, Biological Assessment, In vivo Oral Toxicity Analysis, Docking Studies, Molecular Dynamics, and ADME Profiling;INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY;2023-12

2. Some New Benzotriazole Derivatives: Synthesis, Antimycobacterial Evaluation, Antimicrobial Efficacy, ADME Studies, and Molecular Docking Studies;INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY;2023-09-30

3. Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand;Medicine in Omics;2023-06

4. Designing New Magic Bullets to Penetrate the Mycobacterial Shield: An Arduous Quest for Promising Therapeutic Candidates;Microbial Drug Resistance;2023-05-01

5. Design, synthesis, molecular docking, and biological evaluation of coumarin‐thymidine analogs as potent anti‐TB agents;Archiv der Pharmazie;2023-01-12